Skip to main content

Advertisement

Table 2 miR-503 expression and mRS in acute and chronic phase, NIHSS score, history of hypertension and hyperlipidemia, using antihypertensive and antiplatelet drugs, different clinical manifestations and stroke subtypes in all groups

From: Can MiR-503 be used as a marker in diabetic patients with ischemic stroke?

  Group (I) Group (II) Group (III) Control  
miR-503 expression (acute) 3.3 ± 2.1 1.9 ± 1.5 2.5 ± 1.8 1.1 ± 0.4 P = 0.045
(I), (II): p = 0.02, (II), (III): p = 0.3
(I), (III): p = 0.2 (II), (IV): p = 0.4
(I). (IV): p = 0.016 (III), (IV): p = 0.1
miR-503 expression (chronic) 1.2 ± 0.6 1.3 ± 0.4 2.5 ± 1.8 1.1 ± 0.4 P = 0.009
(I), (II): p = 0.8, (II), (III): p = 0.005
(I), (III): p = 0.004 (II), (IV): p = 0.7
(I), (IV): p = 0.8
NIHSS score 12.2 ± 5.2 11.8 ± 5.3 p > 0.05
mRS acute 3.4 ± 1.2 3.3 ± 1.3 p > 0.05
mRS chronic 2 ± 1.5 3.2 ± 1.9 p > 0.05
Hypertension (Y) 11 (84.6%) 13 (72.2%) 3 (25%) 2 (40%) p > 0.05
Hyperlipidemia (Y) 5 (38.5%) 9 (50%) 4 (33.3%) 2 (40%) p > 0.05
Antihypertensive drug 10 (66.6%) 13 (72.2%) 3 (25%) 2 (40%) p > 0.05
Antiplatelet drug 6 (46.2%) 11 (47.8%) p > 0.05
Clinical manifestation    p > 0.05
 Altered consciousness 2 (13.3%) 7 (38.8%)    
 Diplopia/dysarthria/facial paralysis 10 (76.9%) 8 (44.4%)    
 Hemiparesis/hemisensory deficit 10 (76.9%) 13 (72.2.%)    
Stroke subtype      p > 0.05
 LVA 6 (40%) 10 (52.6%)    
 SVA 8 (53.3%) 6 (31.6%)    
 Cardioembolic 1 (6.7%) 3 (15.8%)